NSE filing, NSE: WANBURY. Summary written from the filing by ALFA Finder's alert engine.
Wanbury Ltd: key numbers
- Share price
- ₹204.51
- Market cap
- ₹715.1 Cr
- Revenue (annual)
- ₹650.3 Cr
- Net profit (annual)
- ₹66.13 Cr
- P/E (TTM)
- 13.6×Sector 43.8×
- Promoter holding
- 42.98%-0.04% QoQ
- FII holding
- 0.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wanbury Ltd
All →Wanbury Q2 FY27 Results: Net Profit ₹11.9 Cr, Down 21.7% YoY
Wanbury Ltd reported revenue from operations of ₹182.9 Cr (+14.2% YoY) and net profit of ₹11.9 Cr (-21.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.9 Cr · -21.7% YoY
Wanbury Business Update
Wanbury's Tanuku plant received an Australian TGA GMP certificate covering six APIs. This strengthens the company's global pharmaceutical manufacturing credentials.
Wanbury Board Meeting Date
Wanbury Limited has scheduled its Board Meeting for 4 Nov 2026 to consider unaudited half-year results. No financial figures or material decisions are disclosed in this advance intimation.
Wanbury Other Announcement
Wanbury Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Wanbury Business Update
Wanbury Limited received nine "No DMF Deficiency" letters from the USFDA for Metformin HCl. The company also expanded its business in Saudi Arabia and Mexico with an annual revenue potential of Rs 25 Crore.
Wanbury Product Launch
Wanbury Skin Health launched its berrysoft baby product range across multiple Indian states. This marks the company's strategic entry into the paediatric dermatology segment.
Other regulatory approval announcements
All →Sandur Manganese & Iron Ores Regulatory Approval
Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.
- iron ore RoM capacity
- 9.42 MTPA
Neogen Chemicals Regulatory Approval
Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.
Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.